Research Collaboration, Option and License Agreement Between Isis Pharmaceuticals, Inc. And Janssen Biotech Inc.Research Collaboration, Option and License Agreement • March 2nd, 2015 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • New York
This RESEARCH COLLABORATION, OPTION AND LICENSE AGREEMENT (the “Agreement”) is entered into as of the 22nd day of December, 2014 (the “Effective Date”), by and between Isis Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 (“Isis”), and Janssen Biotech Inc., a Pennsylvania company, with principal offices located at 800/850 Ridgeview Road, Horsham, PA 19044 (“JBI”) JBI and Isis each may be referred to herein individually as a “Party” or collectively as the “Parties.” Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in Appendix 1. All attached appendices and schedules are a part of this Agreement.
December 15, 2014Sma Agreement • March 2nd, 2015 • Isis Pharmaceuticals Inc • Pharmaceutical preparations
AMENDMENT NO.2Isis Pharmaceuticals Inc • March 2nd, 2015 • Pharmaceutical preparations
This Amendment No.2 (“the “Amendment”) to the Collaboration, License and Development Agreement dated December 7th, 2012 (the “Agreement”), is made by and between
